<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<!-- saved from url=(0052)http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1884432/ -->
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en"><head><meta http-equiv="Content-Type" content="text/html; charset=UTF-8">
        <!-- AppResources meta begin -->
        <script type="text/javascript">var ncbi_startTime = new Date();</script>
        <!-- AppResources meta end -->
        
        <!-- TemplateResources meta begin -->
        <meta name="paf_template" content="">

        <!-- TemplateResources meta end -->
        
        <!-- Logger begin -->
        <meta name="ncbi_db" content="pmc"><meta name="ncbi_pdid" content="article"><meta name="ncbi_acc" content=""><meta name="ncbi_domain" content="brjclinpharm"><meta name="ncbi_report" content="record"><meta name="ncbi_type" content="fulltext"><meta name="ncbi_objectid" content=""><meta name="ncbi_pcid" content="/articles/PMC1884432/"><meta name="ncbi_app" content="pmc">
        <!-- Logger end -->
        
        <title>Effect of rifampicin on pravastatin pharmacokinetics in healthy subjects</title>
        
        <!-- AppResources external_resources begin -->
        <link rel="stylesheet" href="./PMC1884432_files/jig.min.css"><script type="text/javascript" src="./PMC1884432_files/jig.min.js"></script>

        <!-- AppResources external_resources end -->
        
        <!-- Page meta begin -->
        <meta name="robots" content="INDEX,NOFOLLOW,NOARCHIVE"><link rel="canonical" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1884432/"><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/"><meta name="citation_journal_title" content="British Journal of Clinical Pharmacology"><meta name="citation_title" content="Effect of rifampicin on pravastatin pharmacokinetics in healthy subjects"><meta name="citation_authors" content="Carl Kyrklund, Janne T Backman, Mikko Neuvonen, Pertti J Neuvonen"><meta name="citation_date" content="February 2004"><meta name="citation_issue" content="2"><meta name="citation_volume" content="57"><meta name="citation_firstpage" content="181"><meta name="citation_doi" content="10.1046/j.1365-2125.2003.01972.x"><meta name="citation_abstract_html_url" content="/pmc/articles/PMC1884432/?report=abstract"><meta name="citation_pmid" content="14748817"><meta name="DC.Title" content="Effect of rifampicin on pravastatin pharmacokinetics in healthy subjects"><meta name="DC.Type" content="Text"><meta name="DC.Publisher" content="Wiley-Blackwell"><meta name="DC.Contributor" content="Carl Kyrklund"><meta name="DC.Contributor" content="Janne T Backman"><meta name="DC.Contributor" content="Mikko Neuvonen"><meta name="DC.Contributor" content="Pertti J Neuvonen"><meta name="DC.Date" content="2004 Feb"><meta name="DC.Identifier" content="10.1046/j.1365-2125.2003.01972.x"><meta name="DC.Language" content="en"><meta property="og:title" content="Effect of rifampicin on pravastatin pharmacokinetics in healthy subjects"><meta property="og:type" content="article"><meta property="og:description" content="Previous work has shown that rifampicin, a potent inducer of several cytochrome P450 (CYP) enzymes and transporters, decreased the plasma concentrations of simvastatin acid by more than 90%. This study was conducted to investigate the effect of rifampicin ..."><meta property="og:url" content="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1884432/"><meta property="og:site_name" content="PubMed Central (PMC)"><meta property="og:image" content="http://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/pmc-logo-share.png"><meta name="twitter:card" content="summary"><meta name="twitter:site" content="@ncbi"><link rel="stylesheet" href="./PMC1884432_files/pmc.min.css" type="text/css"><link rel="stylesheet" href="./PMC1884432_files/pmc_extras_prnt.min.css" type="text/css" media="print"><script type="text/javascript" src="./PMC1884432_files/common.min.js">//</script><script type="text/javascript" src="./PMC1884432_files/NcbiTagServer.min.js">//</script><meta name="citationexporter" content="backend:&#39;/pmc/utils/ctxp/&#39;"><script type="text/javascript" src="./PMC1884432_files/jquery.citationexporter.js">//</script><link rel="stylesheet" href="./PMC1884432_files/citationexporter.css" type="text/css"><script type="text/javascript" src="./PMC1884432_files/MathJax.js"></script><script type="text/javascript" src="./PMC1884432_files/large-obj-scrollbars.min.js"></script><script type="text/javascript">window.name="mainwindow";</script><style type="text/css">.pmc-wm {background:transparent repeat-y top left;background-image:url(/corehtml/pmc/pmcgifs/wm-brjclinpharm.gif);background-size: auto, contain}</style><style type="text/css">.print-view{display:block}</style><style type="text/css">
        div.pmc_para_cit li.highlight,
        div.pmc_para_cit li.highlight .one_line_source
        { background: #E0E0E0; }
        a.bibr.highlight { background: #E0E0E0; } 
      </style><link rel="alternate" type="application/epub+zip" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1884432/epub/"><link rel="alternate" type="application/pdf" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1884432/pdf/bcp0057-0181.pdf">

        <!-- Page meta end -->
    <link rel="shortcut icon" href="http://www.ncbi.nlm.nih.gov/favicon.ico"><meta name="ncbi_phid" content="F4FB0CF376C271C1000000000021379E"><link type="text/css" rel="stylesheet" href="./PMC1884432_files/3855312.css"><link type="text/css" rel="stylesheet" href="./PMC1884432_files/3929378.css" media="print"><style type="text/css" media="print">.print-log { position:absolute;left:-10000px;top:auto;width:1px;height:1px;overflow:hidden; }.print-log li { list-style-image: url('http://www.ncbi.nlm.nih.gov/stat?jsevent=print&ncbi_app=pmc&ncbi_db=pmc&ncbi_pcid=%2Farticles%2FPMC1884432%2F&ncbi_pdid=article&ncbi_phid=F4FB0CF376C271C1000000000021379E'); }</style><style type="text/css">.print-log { position:absolute;left:-10000px;top:auto;width:1px;height:1px;overflow:hidden; }</style><style type="text/css">.MathJax_Preview {color: #888}
#MathJax_Message {position: fixed; left: 1em; bottom: 1.5em; background-color: #E6E6E6; border: 1px solid #959595; margin: 0px; padding: 2px 8px; z-index: 102; color: black; font-size: 80%; width: auto; white-space: nowrap}
#MathJax_MSIE_Frame {position: absolute; top: 0; left: 0; width: 0px; z-index: 101; border: 0px; margin: 0px; padding: 0px}
.MathJax_Error {color: #CC0000; font-style: italic}
</style><style type="text/css">.MathJax_Hover_Frame {border-radius: .25em; -webkit-border-radius: .25em; -moz-border-radius: .25em; -khtml-border-radius: .25em; box-shadow: 0px 0px 15px #83A; -webkit-box-shadow: 0px 0px 15px #83A; -moz-box-shadow: 0px 0px 15px #83A; -khtml-box-shadow: 0px 0px 15px #83A; border: 1px solid #A6D ! important; display: inline-block; position: absolute}
.MathJax_Menu_Button .MathJax_Hover_Arrow {position: absolute; cursor: pointer; display: inline-block; border: 2px solid #AAA; border-radius: 4px; -webkit-border-radius: 4px; -moz-border-radius: 4px; -khtml-border-radius: 4px; font-family: 'Courier New',Courier; font-size: 9px; color: #F0F0F0}
.MathJax_Menu_Button .MathJax_Hover_Arrow span {display: block; background-color: #AAA; border: 1px solid; border-radius: 3px; line-height: 0; padding: 4px}
.MathJax_Hover_Arrow:hover {color: white!important; border: 2px solid #CCC!important}
.MathJax_Hover_Arrow:hover span {background-color: #CCC!important}
</style><style type="text/css">#MathJax_Zoom {position: absolute; background-color: #F0F0F0; overflow: auto; display: block; z-index: 301; padding: .5em; border: 1px solid black; margin: 0; font-weight: normal; font-style: normal; text-align: left; text-indent: 0; text-transform: none; line-height: normal; letter-spacing: normal; word-spacing: normal; word-wrap: normal; white-space: nowrap; float: none; -webkit-box-sizing: content-box; -moz-box-sizing: content-box; box-sizing: content-box; box-shadow: 5px 5px 15px #AAAAAA; -webkit-box-shadow: 5px 5px 15px #AAAAAA; -moz-box-shadow: 5px 5px 15px #AAAAAA; -khtml-box-shadow: 5px 5px 15px #AAAAAA; filter: progid:DXImageTransform.Microsoft.dropshadow(OffX=2, OffY=2, Color='gray', Positive='true')}
#MathJax_ZoomOverlay {position: absolute; left: 0; top: 0; z-index: 300; display: inline-block; width: 100%; height: 100%; border: 0; padding: 0; margin: 0; background-color: white; opacity: 0; filter: alpha(opacity=0)}
#MathJax_ZoomFrame {position: relative; display: inline-block; height: 0; width: 0}
#MathJax_ZoomEventTrap {position: absolute; left: 0; top: 0; z-index: 302; display: inline-block; border: 0; padding: 0; margin: 0; background-color: white; opacity: 0; filter: alpha(opacity=0)}
</style><style type="text/css">#MathJax_About {position: fixed; left: 50%; width: auto; text-align: center; border: 3px outset; padding: 1em 2em; background-color: #DDDDDD; color: black; cursor: default; font-family: message-box; font-size: 120%; font-style: normal; text-indent: 0; text-transform: none; line-height: normal; letter-spacing: normal; word-spacing: normal; word-wrap: normal; white-space: nowrap; float: none; z-index: 201; border-radius: 15px; -webkit-border-radius: 15px; -moz-border-radius: 15px; -khtml-border-radius: 15px; box-shadow: 0px 10px 20px #808080; -webkit-box-shadow: 0px 10px 20px #808080; -moz-box-shadow: 0px 10px 20px #808080; -khtml-box-shadow: 0px 10px 20px #808080; filter: progid:DXImageTransform.Microsoft.dropshadow(OffX=2, OffY=2, Color='gray', Positive='true')}
#MathJax_About.MathJax_MousePost {outline: none}
.MathJax_Menu {position: absolute; background-color: white; color: black; width: auto; padding: 5px 0px; border: 1px solid #CCCCCC; margin: 0; cursor: default; font: menu; text-align: left; text-indent: 0; text-transform: none; line-height: normal; letter-spacing: normal; word-spacing: normal; word-wrap: normal; white-space: nowrap; float: none; z-index: 201; border-radius: 5px; -webkit-border-radius: 5px; -moz-border-radius: 5px; -khtml-border-radius: 5px; box-shadow: 0px 10px 20px #808080; -webkit-box-shadow: 0px 10px 20px #808080; -moz-box-shadow: 0px 10px 20px #808080; -khtml-box-shadow: 0px 10px 20px #808080; filter: progid:DXImageTransform.Microsoft.dropshadow(OffX=2, OffY=2, Color='gray', Positive='true')}
.MathJax_MenuItem {padding: 1px 2em; background: transparent}
.MathJax_MenuArrow {position: absolute; right: .5em; padding-top: .25em; color: #666666; font-size: .75em}
.MathJax_MenuActive .MathJax_MenuArrow {color: white}
.MathJax_MenuArrow.RTL {left: .5em; right: auto}
.MathJax_MenuCheck {position: absolute; left: .7em}
.MathJax_MenuCheck.RTL {right: .7em; left: auto}
.MathJax_MenuRadioCheck {position: absolute; left: .7em}
.MathJax_MenuRadioCheck.RTL {right: .7em; left: auto}
.MathJax_MenuLabel {padding: 1px 2em 3px 1.33em; font-style: italic}
.MathJax_MenuRule {border-top: 1px solid #DDDDDD; margin: 4px 3px}
.MathJax_MenuDisabled {color: GrayText}
.MathJax_MenuActive {background-color: #606872; color: white}
.MathJax_MenuDisabled:focus, .MathJax_MenuLabel:focus {background-color: #E8E8E8}
.MathJax_ContextMenu:focus {outline: none}
.MathJax_ContextMenu .MathJax_MenuItem:focus {outline: none}
#MathJax_AboutClose {top: .2em; right: .2em}
.MathJax_Menu .MathJax_MenuClose {top: -10px; left: -10px}
.MathJax_MenuClose {position: absolute; cursor: pointer; display: inline-block; border: 2px solid #AAA; border-radius: 18px; -webkit-border-radius: 18px; -moz-border-radius: 18px; -khtml-border-radius: 18px; font-family: 'Courier New',Courier; font-size: 24px; color: #F0F0F0}
.MathJax_MenuClose span {display: block; background-color: #AAA; border: 1.5px solid; border-radius: 18px; -webkit-border-radius: 18px; -moz-border-radius: 18px; -khtml-border-radius: 18px; line-height: 0; padding: 8px 0 6px}
.MathJax_MenuClose:hover {color: white!important; border: 2px solid #CCC!important}
.MathJax_MenuClose:hover span {background-color: #CCC!important}
.MathJax_MenuClose:hover:focus {outline: none}
</style></head>
    <body class="article" id="ui-jig-5"><div id="MathJax_Message" style="display: none;"></div>
        <div class="grid">
            <div class="col twelve_col nomargin shadow">
                <!-- System messages like service outage or JS required; this is handled by the TemplateResources portlet -->
                <div class="sysmessages">
                    <noscript>
	&lt;p class="nojs"&gt;
	&lt;strong&gt;Warning:&lt;/strong&gt;
	The NCBI web site requires JavaScript to function. 
	&lt;a href="/guide/browsers/#enablejs" title="Learn how to enable JavaScript" target="_blank"&gt;more...&lt;/a&gt;
	&lt;/p&gt;
	</noscript>
                </div>
                <!--/.sysmessage-->
                <div class="wrap">
                    <div class="page">
                        <div class="top">
                            <div class="universal_header" id="universal_header"><ul class="inline_list jig-ncbimenu ui-ncbimenu resources_list ui-ncbibasicmenu orientation_hort" id="navcontent" role="menubar"><li class="ui-ncbimenu-item-leaf ui-ncbimenu-item-first ui-helper-reset ui-ncbimenu-item-no-hlt" role="presentation"><a class="ui-ncbimenu-link-first" href="http://www.ncbi.nlm.nih.gov/" role="menuitem" title="NCBI Home" id="ncbihome" accesskey="1"><span class="offscreen_noflow">NCBI</span><img src="./PMC1884432_files/28977" class="ncbi_logo" title="NCBI" alt="NCBI Logo"></a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1884432/#maincontent" title="Skip to the content" tabindex="0" accesskey="3">Skip to main
                        content</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1884432/#navcontent" title="Skip to the navigation" tabindex="0" accesskey="4">Skip to
                        navigation</a></li><li id="resource-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first ui-helper-reset" role="presentation"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="http://www.ncbi.nlm.nih.gov/static/header_footer_ajax/submenu/#resources" tabindex="-1" role="menuitem">Resources</a></li><li id="all-howtos-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first" role="presentation"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="http://www.ncbi.nlm.nih.gov/static/header_footer_ajax/submenu/#howto" tabindex="-1" role="menuitem">How To</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="http://www.ncbi.nlm.nih.gov/guide/browsers/#accesskeys" title="About My NCBI Accesskeys" tabindex="0" accesskey="0">About NCBI Accesskeys</a></li></ul><div class="myncbi"><span id="myncbiusername" style="display:none"><a href="http://www.ncbi.nlm.nih.gov/account/settings/" id="mnu" title="Edit account settings"></a></span><a accesskey="2" href="http://www.ncbi.nlm.nih.gov/myncbi/" id="myncbi" style="display:none">My NCBI</a><a href="http://www.ncbi.nlm.nih.gov/account/?back_url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC1884432%2F" id="sign_in">Sign in to NCBI</a><a href="http://www.ncbi.nlm.nih.gov/account/signout/?back_url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC1884432%2F" id="sign_out" style="display:none">Sign Out</a></div></div>
                            <div class="header">
    <div class="res_logo">
  <h1 class="img_logo"><a href="http://www.ncbi.nlm.nih.gov/pmc/" class="pmc_logo offscreen">PMC</a></h1>
  <div class="NLMLogo">
    <a href="http://www.nlm.nih.gov/" title="US National Library of Medicine">US National Library of Medicine</a>
    <br>
    <a href="http://www.nih.gov/" title="National Institutes of Health">National Institutes of Health</a>
  </div>
</div>
    <div class="search"><form method="get" action="http://www.ncbi.nlm.nih.gov/pmc/"><div class="search_form"><label for="database" class="offscreen_noflow">Search database</label><select id="database"><optgroup label="Recent"><option value="pmc" selected="selected" data-ac_dict="pmc-search-autocomplete">PMC</option><option value="pubmed" class="last">PubMed</option></optgroup><optgroup label="All"><option value="gquery">All Databases</option><option value="assembly">Assembly</option><option value="bioproject">BioProject</option><option value="biosample">BioSample</option><option value="biosystems">BioSystems</option><option value="books">Books</option><option value="clinvar">ClinVar</option><option value="clone">Clone</option><option value="cdd">Conserved Domains</option><option value="gap">dbGaP</option><option value="dbvar">dbVar</option><option value="nucest">EST</option><option value="gene">Gene</option><option value="genome">Genome</option><option value="gds">GEO DataSets</option><option value="geoprofiles">GEO Profiles</option><option value="nucgss">GSS</option><option value="gtr">GTR</option><option value="homologene">HomoloGene</option><option value="medgen">MedGen</option><option value="mesh">MeSH</option><option value="ncbisearch">NCBI Web Site</option><option value="nlmcatalog">NLM Catalog</option><option value="nuccore">Nucleotide</option><option value="omim">OMIM</option><option value="pmc" data-ac_dict="pmc-search-autocomplete">PMC</option><option value="popset">PopSet</option><option value="probe">Probe</option><option value="protein">Protein</option><option value="proteinclusters">Protein Clusters</option><option value="pcassay">PubChem BioAssay</option><option value="pccompound">PubChem Compound</option><option value="pcsubstance">PubChem Substance</option><option value="pubmed">PubMed</option><option value="pubmedhealth">PubMed Health</option><option value="snp">SNP</option><option value="sra">SRA</option><option value="structure">Structure</option><option value="taxonomy">Taxonomy</option><option value="toolkit">ToolKit</option><option value="toolkitall">ToolKitAll</option><option value="toolkitbook">ToolKitBook</option><option value="toolkitbookgh">ToolKitBookgh</option><option value="unigene">UniGene</option></optgroup></select><div class="nowrap"><label for="term" class="offscreen_noflow" accesskey="/">Search term</label><div class="nowrap"><div class="ui-ncbiclearbutton-wrap box-shadow"><input type="text" name="term" id="term" title="Search PMC. Use up and down arrows to choose an item from the autocomplete." value="" class="jig-ncbiclearbutton jig-ncbiautocomplete" config="dictionary:&#39;pmc-search-autocomplete&#39;,disableUrl:&#39;NcbiSearchBarAutoComplCtrl&#39;" autocomplete="off" data-sbconfig="ds:&#39;no&#39;,pjs:&#39;no&#39;,afs:&#39;yes&#39;" aria-haspopup="true" aria-autocomplete="list" role="textbox"><a class="reset" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1884432/#" style="visibility: hidden;"><img src="./PMC1884432_files/clear.png" alt="Clear input"></a></div></div><button id="search" type="submit" class="button_search nowrap" cmd="go">Search</button></div></div></form><ul class="searchlinks inline_list"><li>
                        <a href="http://www.ncbi.nlm.nih.gov/pmc/limits/">Limits</a>
                    </li><li>
                        <a href="http://www.ncbi.nlm.nih.gov/pmc/advanced/">Advanced</a>
                    </li><li>
                        <a href="http://www.ncbi.nlm.nih.gov/pmc/journals/">Journal list</a>
                    </li><li class="help">
                        <a target="_blank" href="http://www.ncbi.nlm.nih.gov/books/NBK3825/">Help</a>
                    </li></ul></div>
</div>

                            
                            
                        <!--<component id="Page" label="headcontent"/>-->
                            
                        </div>
                        <div class="content">
                            <!-- site messages -->
                            <div class="container">
    <div id="maincontent" class="content eight_col col">
        <div class="navlink-box">
            <ul class="page-breadcrumbs inline_list small"><li class="journal-list"><a href="http://www.ncbi.nlm.nih.gov/pmc/journals/" class="navlink">Journal List</a></li><li class="archive-page"><a class="navlink" href="http://www.ncbi.nlm.nih.gov/pmc/journals/279/">Br J Clin Pharmacol</a></li><li class="issue-page"><a class="navlink" href="http://www.ncbi.nlm.nih.gov/pmc/issues/144672/">v.57(2); 2004 Feb</a></li><li class="accid">PMC1884432</li></ul>
        </div>

        <!-- Journal banner -->
        <div class="pmc-page-banner whole_rhythm"><div><img src="./PMC1884432_files/logo-brjclinpharm.gif" alt="Logo of brjclinpharm" usemap="#logo-imagemap"><map id="logo-imagemap" name="logo-imagemap"><area alt="Link to Publisher&#39;s site" title="Link to Publisher&#39;s site" shape="default" coords="0,0,499,74" href="http://www.blackwellpublishing.com/journal.asp?ref=0306-5251" target="pmc_ext" ref="reftype=publisher&amp;article-id=1884432&amp;issue-id=144672&amp;journal-id=279&amp;FROM=Article%7CBanner&amp;TO=Publisher%7COther%7CN/A&amp;rendering-type=normal"></map></div> </div>
        
        <!--component id='MainPortlet' label='search-reference'/-->
        
        <!-- Book content -->
        <div class="">
            
        
            
            <div class="hide-overflow article lit-style content pmc-wm slang-all page-box"><!--main-content--><div class="jig-ncbiinpagenav" data-jigconfig="smoothScroll: false, allHeadingLevels: [&#39;h2&#39;], headingExclude: &#39;:hidden&#39;" id="ui-jig-1"><div class="fm-sec half_rhythm no_top_margin"><div class="fm-citation half_rhythm no_top_margin clearfix"><div class="small"><div class="inline_block eight_col va_top"><div><div><span class="cit">Br J Clin Pharmacol. 2004 Feb; 57(2): 181–187. </span></div><div>  <span class="doi">doi:&nbsp; <a href="http://dx.doi.org/10.1046%2Fj.1365-2125.2003.01972.x" target="pmc_ext" ref="reftype=other&amp;article-id=1884432&amp;issue-id=144672&amp;journal-id=279&amp;FROM=Article%7CFront%20Matter&amp;TO=Content%20Provider%7CCrosslink%7CDOI&amp;rendering-type=normal">10.1046/j.1365-2125.2003.01972.x</a></span></div></div></div><div class="inline_block four_col va_top show-overflow align_right"><div class="fm-citation-ids"><div class="fm-citation-pmcid"><span class="fm-citation-ids-label">PMCID: </span><span>PMC1884432</span></div></div></div></div></div><h1 class="content-title">Effect of rifampicin on pravastatin pharmacokinetics in healthy subjects</h1><div class="half_rhythm"><div class="contrib-group fm-author"><a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=Kyrklund%20C%5Bauth%5D">Carl Kyrklund</a>, <a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=Backman%20JT%5Bauth%5D">Janne T Backman</a>, <a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=Neuvonen%20M%5Bauth%5D">Mikko Neuvonen</a>, and  <a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=Neuvonen%20PJ%5Bauth%5D">Pertti J Neuvonen</a></div></div><div class="fm-panel small half_rhythm"><div class="fm-authors-info fm-panel hide half_rhythm" id="id658724_ai" style="display:none"><div class="fm-affl" lang="en">Department of Clinical Pharmacology, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland</div><div id="cor1">Correspondence Janne T. Backman, Department of Clinical Pharmacology, University of Helsinki, Haartmaninkatu 4, FIN-00290 Helsinki, Finland. Tel: +358 9 471 74036 Fax: +358 9 471 74039 E-mail: <a href="mailto:dev@null" data-email="if.suh@namkcab.ennaj" class="oemail">if.suh@namkcab.ennaj</a></div><div id="__fnid632166">This study was supported by grants from the Helsinki University Central Hospital Research Fund and the National Technology Agency (Tekes).</div></div><div class="togglers"><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1884432/#" class="pmctoggle" rid="id658724_ai">Author information <span>►</span></a> <a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1884432/#" class="pmctoggle" rid="id658724_an">Article notes <span>►</span></a> <a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1884432/#" class="pmctoggle" rid="id658724_cpl">Copyright and License information <span>►</span></a></div><div class="fm-article-notes fm-panel hide half_rhythm" id="id658724_an" style="display:none"><div class="fm-pubdate half_rhythm">Received 2003 May 5; Accepted 2003 Aug 1.</div></div><div class="fm-cpl-info fm-panel hide half_rhythm" id="id658724_cpl" style="display:none"><div class="fm-copyright half_rhythm"><a href="http://www.ncbi.nlm.nih.gov/pmc/about/copyright.html">Copyright</a> © 2003 Blackwell Publishing Ltd</div></div></div><div class="links-box fm-panel whole_rhythm"><div class="small"><div>This article has been <a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1884432/citedby/">cited by</a> other articles in PMC.</div></div></div></div><div class="sec"></div><div id="__abstractid623016" lang="en" class="tsec sec"><div class="goto jig-ncbiinpagenav-goto-container" id="ui-jig-7"><span role="menubar"><a class="tgt_dark page-toc-label jig-ncbiinpagenav-goto-heading" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1884432/#" title="Go to other sections in this page" role="menuitem" aria-expanded="false" aria-haspopup="true" id="ui-jig-8">Go to:</a></span></div><h2 class="head no_bottom_margin ui-helper-clearfix" id="__abstractid623016title">Abstract</h2><!--article-meta--><div><div id="__sec1" class="sec sec-first"><h3>Aims</h3><p id="__p2" class="p p-first-last">Previous work has shown that rifampicin, a potent inducer of several cytochrome P450 (CYP) enzymes and transporters, decreased the plasma concentrations of simvastatin acid by more than 90%. This study was conducted to investigate the effect of rifampicin on the pharmacokinetics of pravastatin.</p></div><div id="__sec2" class="sec"><h3>Methods</h3><p id="__p3" class="p p-first-last">In a randomised, cross-over two-phase study with a washout of 4 weeks, 10 healthy volunteers received a 5-day pretreatment with rifampicin (600 mg daily) or placebo. On day 6, a single 40 mg dose of pravastatin was administered orally. Plasma concentrations of pravastatin were measured up to 12 h by a sensitive LC-MS-MS method.</p></div><div id="__sec3" class="sec"><h3>Results</h3><p id="__p4" class="p p-first-last">During the rifampicin phase, the mean total area under the plasma concentration-time curve of pravastatin [AUC(0–∞)] was 69% (range 24–220%) of the corresponding value during the placebo phase (<em>P</em> &lt; 0.05, 95% confidence interval for the difference −51.9–−0.4 ng ml<sup>−1</sup>·h). In five of the 10 subjects the AUC(0–∞) of pravastatin during the rifampicin phase was 50% or less of that during the placebo phase. Rifampicin had no significant effect on the peak concentration, elimination half-life or renal clearance of pravastatin.</p></div><div id="__sec4" class="sec sec-last"><h3>Conclusions</h3><p id="__p5" class="p p-first-last">Rifampicin caused a statistically significant decrease in the plasma concentration of pravastatin given as a single oral dose to healthy subjects. However, the effect of rifampicin varied greatly between subjects. The mean rifampicin-induced decrease in pravastatin concentration was considerably smaller than that observed previously for simvastatin.</p></div></div><div class="sec"><strong class="kwd-title">Keywords: </strong><span class="kwd-text">interaction, pravastatin, rifampicin</span></div></div><div id="__sec5" class="tsec sec"><div class="goto jig-ncbiinpagenav-goto-container" id="ui-jig-9"><a class="tgt_dark page-toc-label jig-ncbiinpagenav-goto-heading" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1884432/#" title="Go to other sections in this page" role="button" aria-expanded="false" aria-haspopup="true" id="ui-jig-10">Go to:</a></div><h2 class="head no_bottom_margin ui-helper-clearfix" id="__sec5title">Introduction</h2><p id="__p6" class="p p-first">Rifampicin is a potent inducer of several cytochrome P450 (CYP) enzymes both in the intestinal wall and the liver [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1884432/#b1" rid="b1" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_137260738">1</a>–<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1884432/#b3" rid="b3" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_137260726">3</a>]. Rifampicin also induces the expression of some drug transporters, for example the efflux transporters P-glycoprotein [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1884432/#b4" rid="b4" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_137260729">4</a>] and canalicular multispecific organic anion transporter (cMOAT, or MRP2) [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1884432/#b5" rid="b5" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_137260707">5</a>]. Induction of CYP enzymes and drug transporters by rifampicin is mediated by the activation of the nuclear pregnane X receptor (PXR) [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1884432/#b6" rid="b6" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_137260706">6</a>, <a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1884432/#b7" rid="b7" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_137260704">7</a>]. Organic anion transporting polypeptide (OATP) family members OATP2 (OATP-C or LST-1) and OATP8 (LST-2) can mediate the uptake of rifampicin into liver cells, and thus facilitate rifampicin mediated PXR activation [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1884432/#b8" rid="b8" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_137260703">8</a>]. Recently we showed that rifampicin decreases the total area under the plasma concentration-time curve (AUC) and peak concentration (<em>C</em><sub><em>max</em></sub>) of the HMG-CoA inhibitor simvastatin and its acid metabolite to about one tenth of control values [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1884432/#b9" rid="b9" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_137260711">9</a>].</p><p id="__p7" class="p p-last">Unlike simvastatin, the metabolism of pravastatin is not significantly mediated by CYP enzymes [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1884432/#b10" rid="b10" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_137260739">10</a>–<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1884432/#b12" rid="b12" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_137260732">12</a>]. However, pravastatin is a substrate of MRP2 and the uptake transporter OATP2 [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1884432/#b13" rid="b13" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_137260730">13</a>–<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1884432/#b15" rid="b15" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_137260720">15</a>]. Recent studies have illustrated differences in the interaction potential of the different statin drugs. Thus, itraconazole increased the AUC of simvastatin acid at least tenfold but had no significant effect on that of pravastatin [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1884432/#b16" rid="b16" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_137260712">16</a>]. Furthermore, combination therapy with the HIV protease inhibitors ritonavir and saquinavir increased the median AUC(0–24) of simvastatin 30-fold, but decreased that of pravastatin by 50% [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1884432/#b17" rid="b17" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_308926919">17</a>]. Pravastatin is a substrate of both influx and efflux transporters, and although significant interactions mediated by induction of pravastatin metabolism are not likely, the <em>in vivo</em> effects of induction of transporters are largely unknown. Thus, the extent of any interaction between rifampicin and pravastatin cannot be inferred from previous work. The aim of this study was to examine the possible effect of rifampicin on the pharmacokinetics of pravastatin in healthy volunteers, using an identical study design as in the previous study to allow comparison of the interaction potentials of simvastatin and pravastatin [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1884432/#b9" rid="b9" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_137260722">9</a>].</p></div><div id="__sec6" class="tsec sec"><div class="goto jig-ncbiinpagenav-goto-container" id="ui-jig-11"><a class="tgt_dark page-toc-label jig-ncbiinpagenav-goto-heading" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1884432/#" title="Go to other sections in this page" role="button" aria-expanded="false" aria-haspopup="true" id="ui-jig-12">Go to:</a></div><h2 class="head no_bottom_margin ui-helper-clearfix" id="__sec6title">Methods</h2><div id="__sec7" class="sec sec-first"><h3>Subjects</h3><p id="__p8" class="p p-first">Ten healthy nonsmoking volunteers (age range, 19–25 years; weight range, 52–103 kg) participated in the study (<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1884432/table/tbl1/" target="true" class="fig-table-link table figpopup" rid-figpopup="tbl1" rid-ob="ob-tbl1" co-legend-rid=""><span>Table 1</span></a>) after giving their written informed consent. The subjects were ascertained to be healthy by a medical history, a physical examination, and routine blood chemistry tests before they entered the study. None of the subjects used oral contraceptives or other continuous medications. The sample size was chosen so that a possible clinically significant pharmacokinetic drug interaction can be verified statistically without the use of an unnecessarily large group of healthy subjects. The statistical power was estimated to be sufficient to detect a 50% change in the AUC of pravastatin with a power of 80% (alpha-level 5%).</p><!--table ft1--><!--table-wrap mode=article t1--><div class="table-wrap iconblock ten_col whole_rhythm clearfix" id="tbl1"><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1884432/table/tbl1/" target="table" rid-ob="ob-tbl1" rid-figpopup="tbl1" class="table img_link icnblk_img figpopup"><img alt="Table 1" title="Table 1" class="small-thumb" src="./PMC1884432_files/saved_resource" src-large="/pmc/articles/PMC1884432/table/tbl1/?report=previmg"></a><div class="icnblk_cntnt"><div><a class="figpopup" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1884432/table/tbl1/" target="table" rid-figpopup="tbl1" rid-ob="ob-tbl1">Table 1</a></div><!--caption a4--><div><span>Characteristics of the subjects</span></div></div></div></div><div id="__sec8" class="sec"><h3>Study design</h3><p id="__p10" class="p p-first-last">The study protocol was approved by the Ethics Committee for Studies in Healthy Subjects, Hospital District of Helsinki and Uusimaa, and the Finnish National Agency for Medicines. A randomized, placebo-controlled, cross-over study design with 2 phases was used. The wash-out period between the phases was 4 weeks. Subjects were given either 600 mg rifampicin (Rifarm, Pharmacal, Helsinki, Finland) or matched placebo orally once daily at 4 p.m. for 5 days. On day 6, pravastatin (a single Pravachol 40 mg tablet, Bristol-Myers Squibb, New York, NY) was administered orally with 150 ml water at 9 AM, that is 17 h after the last dose of rifampicin. The subjects had fasted overnight, and a standard meal was served 3 and 7 h after the administration of pravastatin. Alcohol or strenuous exercise was not allowed for two days and subjects didn't ingest grapefruit juice or other drugs for two weeks before test days. The study design was otherwise identical to our previous rifampicin-simvastatin study [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1884432/#b9" rid="b9" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_137260733">9</a>].</p></div><div id="__sec9" class="sec"><h3>Blood and urine sampling</h3><p id="__p11" class="p p-first-last">Blood samples (10 ml each) were drawn from a cannulated forearm vein prior to administration of pravastatin and 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, and 12 h later, and were collected in tubes containing ethylenediaminetetra-acetic acid (EDTA). Plasma was separated within 30 min and stored at −70 °C until analysis. Urine was collected cumulatively from 0–12 h after the administration of pravastatin.</p></div><div id="__sec10" class="sec"><h3>Determination of pravastatin</h3><p id="__p12" class="p p-first-last">The concentrations of pravastatin in plasma and urine were measured by liquid chromatography-ionspray tandem mass spectrometry with use of the PE SCIEX API 3000 LC/MS/MS system (Sciex Division of MDS Inc, Toronto, Canada) as described previously [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1884432/#b18" rid="b18" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_137260737">18</a>]. The ion transition monitored was <em>m/z</em> 442 to <em>m/z</em> 269, and the limit of quantification was 0.25 ng ml<sup>−1</sup>. The day-to-day coefficients of variation (CV) were 9.0% at 1 ng ml<sup>−1</sup>, 2.6% at 10 ng ml<sup>−1</sup> and 3.3% at 100 ng ml<sup>−1</sup> (<em>n</em> = 7) replicates.</p></div><div id="__sec11" class="sec"><h3>Pharmacokinetic analysis</h3><p id="__p13" class="p p-first-last"><em>C</em><sub><em>max</em></sub> and <em>t</em><sub><em>max</em></sub> were taken directly from the original data. The terminal log-linear phase of the plasma concentration-time curve was identified visually for each curve. The elimination rate constant (k<sub>e</sub>) was determined by a linear regression analysis using the last 3–8 points on the plot of the natural logarithm of the plasma concentration-time curve. The <em>t</em><sub>1/2</sub> was calculated from the equation <em>t</em><sub>1/2</sub> = ln2/k<sub>e</sub>. AUC values were calculated by the linear trapezoidal rule for the rising phase and the log-linear trapezoidal rule for the descending phase, with extrapolation to infinity, when appropriate, by dividing the last measured concentration by k<sub>e</sub>. The renal clearance (CL<sub>renal 0−12 h</sub>) of pravastatin was calculated from CL<sub>renal 0–12 h</sub> = Ae/AUC(0–12), where Ae is the amount of pravastatin excreted into urine within 12 h.</p></div><div id="__sec12" class="sec sec-last"><h3>Statistical analysis</h3><p id="__p14" class="p p-first-last">Results are expressed as mean values (± s.d.) in text and tables and, for clarity, as mean values (± s.e.mean) in the figures. 95% confidence intervals were calculated on the mean differences between the placebo and rifampicin phases for AUC(0–∞), <em>C</em><sub><em>max</em></sub> and <em>t</em><sub>1/2</sub>. Statistical comparisons of the pharmacokinetic variables (except <em>t</em><sub><em>max</em></sub>) were carried out by the Student <em>t</em>-test for paired values (two-tailed), and the Wilcoxon signed-rank test was used for analysis of <em>t</em><sub><em>max</em></sub>. Logarithmic transformation of <em>C</em><sub><em>max</em></sub> and AUC values was done before statistical analysis. The Mann–Whitney <em>U</em>-test was used to compare the effect of rifampicin on the AUC(0–∞) of pravastatin and simvastatin acid [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1884432/#b9" rid="b9" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_137260728">9</a>]. The analysis was performed with Systat for Windows, V6.0.1 (SPSS Inc., Chicago, Ill). The level of statistical significance was <em>P</em> &lt;0.05.</p></div></div><div id="__sec13" class="tsec sec"><div class="goto jig-ncbiinpagenav-goto-container" id="ui-jig-13"><a class="tgt_dark page-toc-label jig-ncbiinpagenav-goto-heading" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1884432/#" title="Go to other sections in this page" role="button" aria-expanded="false" aria-haspopup="true" id="ui-jig-14">Go to:</a></div><h2 class="head no_bottom_margin ui-helper-clearfix" id="__sec13title">Results</h2><p id="__p15" class="p p-first">During the rifampicin phase, the mean AUC(0–∞) of pravastatin was 69% (range 24–220%, <em>P</em> &lt;0.05) of the corresponding value during the placebo phase (<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1884432/figure/fig01/" target="figure" class="fig-table-link fig figpopup" rid-figpopup="fig01" rid-ob="ob-fig01" co-legend-rid="lgnd_fig01"><span>Figure 1</span></a>, <a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1884432/table/tbl2/" target="true" class="fig-table-link table figpopup" rid-figpopup="tbl2" rid-ob="ob-tbl2" co-legend-rid=""><span>Table 2</span></a>). However, there were large interindividual differences in the effect of rifampicin. Thus, the AUC(0–∞) of pravastatin decreased in 7 and increased in 3 of the 10 subjects. This effect was not related to the AUC of pravastatin during the placebo phase or to the gender of the subjects (<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1884432/figure/fig02/" target="figure" class="fig-table-link fig figpopup" rid-figpopup="fig02" rid-ob="ob-fig02" co-legend-rid="lgnd_fig02"><span>Figure 2</span></a>). Rifampicin tended to decrease the <em>C</em><sub><em>max</em></sub> of pravastatin, on average by 21%, but the difference did not reach statistical significance (<em>P</em> = 0.13). Rifampicin had no statistically significant effect on the <em>t</em><sub><em>max</em></sub> (<em>P</em> = 0.33) or <em>t</em><sub>1/2</sub> (<em>P</em> = 0.75) of pravastatin (<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1884432/table/tbl2/" target="true" class="fig-table-link table figpopup" rid-figpopup="tbl2" rid-ob="ob-tbl2" co-legend-rid=""><span>Table 2</span></a>). The renal clearance and the cumulative excretion of pravastatin into the urine were largely unaffected by rifampicin (<em>P</em> = 0.14 and <em>P</em> = 0.35, respectively).</p><!--table ft1--><!--table-wrap mode=article t1--><div class="table-wrap iconblock ten_col whole_rhythm clearfix" id="tbl2"><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1884432/table/tbl2/" target="table" rid-ob="ob-tbl2" rid-figpopup="tbl2" class="table img_link icnblk_img figpopup"><img alt="Table 2" title="Table 2" class="small-thumb" src="./PMC1884432_files/saved_resource(1)" src-large="/pmc/articles/PMC1884432/table/tbl2/?report=previmg"></a><div class="icnblk_cntnt"><div><a class="figpopup" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1884432/table/tbl2/" target="table" rid-figpopup="tbl2" rid-ob="ob-tbl2">Table 2</a></div><!--caption a4--><div><span>The pharmacokinetic variables of pravastatin in 10 healthy subjects after the ingestion of 40 mg pravastatin following treatment with 600 mg rifampicin or placebo twice daily for 5 days</span></div></div></div><!--fig ft0--><!--fig mode=article f1--><div class="fig iconblock ten_col whole_rhythm clearfix" id="fig01" co-legend-rid="lgnd_fig01"><a class="icnblk_img figpopup" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1884432/figure/fig01/" target="figure" rid-figpopup="fig01" rid-ob="ob-fig01"><img src="./PMC1884432_files/bcp0057-0181-f1.gif" class="small-thumb" alt="Figure 1" title="Figure 1" src-large="/pmc/articles/PMC1884432/bin/bcp0057-0181-f1.jpg"></a><div class="icnblk_cntnt" id="lgnd_fig01"><div><a class="figpopup" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1884432/figure/fig01/" target="figure" rid-figpopup="fig01" rid-ob="ob-fig01">Figure 1</a></div><!--caption a4--><div><span>Plasma concentrations (mean ± s.e.mean) of pravastatin in 10 healthy subjects after administration of 40 mg pravastatin following pretreatment with 600 mg rifampicin (•) or placebo (○) once daily for five days.</span></div></div></div><!--fig ft0--><!--fig mode=article f1--><div class="fig iconblock ten_col whole_rhythm clearfix" id="fig02" co-legend-rid="lgnd_fig02"><a class="icnblk_img figpopup" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1884432/figure/fig02/" target="figure" rid-figpopup="fig02" rid-ob="ob-fig02"><img src="./PMC1884432_files/bcp0057-0181-f2.gif" class="small-thumb" alt="Figure 2" title="Figure 2" src-large="/pmc/articles/PMC1884432/bin/bcp0057-0181-f2.jpg"></a><div class="icnblk_cntnt" id="lgnd_fig02"><div><a class="figpopup" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1884432/figure/fig02/" target="figure" rid-figpopup="fig02" rid-ob="ob-fig02">Figure 2</a></div><!--caption a4--><div><span>Individual total area under the concentration-time curve (AUC<sub>tot</sub>), peak plasma concentration (<em>C</em><sub><em>max</em></sub>), renal clearance (CL<sub>renal</sub>) and elimination half-life (T<sub>1/2</sub>) values of pravastatin in 10 healthy subjects after ingestion of 40 mg pravastatin following</span> <strong>...</strong></div></div></div><p id="__p20" class="p">The mean effect of rifampicin on the AUC of pravastatin in the present study was considerably smaller and more variable than that on the AUC of simvastatin acid in our previous study using an identical protocol (<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1884432/figure/fig03/" target="figure" class="fig-table-link fig figpopup" rid-figpopup="fig03" rid-ob="ob-fig03" co-legend-rid="lgnd_fig03"><span>Figure 3</span></a>) [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1884432/#b9" rid="b9" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_137260725">9</a>]. The difference in the effect of rifampicin on the AUC(0–∞) of pravastatin compared to simvastatin acid was statistically significant (<em>P</em> &lt; 0.001).</p><!--fig ft0--><!--fig mode=article f1--><div class="fig iconblock ten_col whole_rhythm clearfix" id="fig03" co-legend-rid="lgnd_fig03"><a class="icnblk_img figpopup" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1884432/figure/fig03/" target="figure" rid-figpopup="fig03" rid-ob="ob-fig03"><img src="./PMC1884432_files/bcp0057-0181-f3.gif" class="small-thumb" alt="Figure 3" title="Figure 3" src-large="/pmc/articles/PMC1884432/bin/bcp0057-0181-f3.jpg"></a><div class="icnblk_cntnt" id="lgnd_fig03"><div><a class="figpopup" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1884432/figure/fig03/" target="figure" rid-figpopup="fig03" rid-ob="ob-fig03">Figure 3</a></div><!--caption a4--><div><span>Effect of an identical pretreatment with 600 mg rifampicin once daily for five days on the areas under the plasma concentration-time curve [AUC(0–∞)] of simvastatin acid and pravastatin as percent of control values. The simvastatin acid</span> <strong>...</strong></div></div></div></div><div id="__sec14" class="tsec sec"><div class="goto jig-ncbiinpagenav-goto-container" id="ui-jig-15"><a class="tgt_dark page-toc-label jig-ncbiinpagenav-goto-heading" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1884432/#" title="Go to other sections in this page" role="button" aria-expanded="false" aria-haspopup="true" id="ui-jig-16">Go to:</a></div><h2 class="head no_bottom_margin ui-helper-clearfix" id="__sec14title">Discussion</h2><p id="__p22" class="p p-first">In this study the plasma concentrations of pravastatin were moderately decreased by pretreatment with rifampicin. The mean AUC(0–∞) of pravastatin was decreased by 31%, but there was considerable interindividual variation. In five of the 10 subjects the AUC(0–∞) of pravastatin during the rifampicin phase was 50% or less of that during the placebo phase. However, in three subjects the plasma concentrations of pravastatin increased during the rifampicin phase. The other pharmacokinetic variables studied were not altered to a statistically significant degree. Although the effect of rifampicin was statistically significant, the possibility of chance finding cannot be excluded. In any case, carry over or period effects did not explain the observations.</p><p id="__p23">The effect of rifampicin on pravastatin pharmacokinetics is not likely to be caused by induction of CYP3A4 or P-glycoprotein, because pravastatin is not a substrate of P-glycoprotein, CYP3A4 or other CYP enzymes [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1884432/#b10" rid="b10" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_137260740">10</a>, <a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1884432/#b11" rid="b11" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_137260715">11</a>, <a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1884432/#b19" rid="b19" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_137260710">19</a>–<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1884432/#b21" rid="b21" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_137260723">21</a>]. However, pravastatin is a substrate of canalicular multispecific organic anion transporter (cMOAT or MRP2) [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1884432/#b13" rid="b13" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_137260734">13</a>], expressed in the kidney, liver and intestine [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1884432/#b22" rid="b22" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_137260735">22</a>]. This efflux transporter can affect the absorption, tissue uptake and elimination of substrate drugs. Rifampicin is known to induce duodenal MRP2 mRNA and MRP2 protein [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1884432/#b5" rid="b5" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_137260717">5</a>], which may result in a decreased exposure to substrates of this transporter. Induction of canalicular MRP2 by rifampicin might also decrease systemic pravastatin absorption by enhancing first-pass biliary excretion. Therefore, it is possible that the observed rifampicin–pravastatin interaction is a consequence of an effect of rifampicin on MRP2 or other transporting proteins. Fromm et al. [5] observed that rifampicin induced duodenal MRP2 protein in only 10 out of the 16 subjects [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1884432/#b5" rid="b5" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_137260708">5</a>], which is in line with our results that rifampicin only decreased pravastatin AUC in 7 out of 10 subjects (<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1884432/figure/fig02/" target="figure" class="fig-table-link fig figpopup" rid-figpopup="fig02" rid-ob="ob-fig02" co-legend-rid="lgnd_fig02"><span>Figure 2</span></a>). There are several allelic variants of OATP2 (OATP-C), an uptake transporter expressed exclusively in the liver sinusoidal membrane, which decrease cellular rifampicin retention and thus could cause interindividual variability in the activation of PXR receptors and consequent induction [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1884432/#b8" rid="b8" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_137260709">8</a>]. An explanation for the increase in pravastatin concentrations in some subjects might be the inhibition of OATP2-mediated uptake of pravastatin into hepatocytes by rifampicin [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1884432/#b8" rid="b8" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_137260736">8</a>]. However, it is likely that the concentrations of rifampicin in the liver were very low at the time of pravastatin administration, because the last dose of rifampicin was administered 17 h earlier. Accordingly, it is also possible that the increase in pravastatin concentrations in some subjects was the result of the inherent variability of pravastatin AUC within an individual.</p><p id="__p24">Glucuronidation appears to be one of the predominant pathways of pravastatin metabolism [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1884432/#b12" rid="b12" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_137260731">12</a>], and rifampicin is also known to induce the phase II enzymes, such as UDP-glucuronosyltransferases [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1884432/#b24" rid="b24" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_137260721">24</a>–<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1884432/#b26" rid="b26" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_137260714">26</a>]. Nevertheless, because the renal clearance and elimination half-life of pravastatin were largely unaffected by rifampicin, it is reasonable to assume that the interaction occurred primarily during the absorption rather than the elimination phase.</p><p id="__p25">Recently, we showed that using an identical protocol, pretreatment with rifampicin greatly decreased the AUC(0–∞) of simvastatin and simvastatin acid in all of the 10 subjects studied [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1884432/#b9" rid="b9" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_137260713">9</a>]. This effect was much greater than that on the pharmacokinetics of pravastatin observed in the present study. In other work, itraconazole was found to increase the AUC(0–∞) and <em>C</em><sub><em>max</em></sub> of simvastatin acid at least tenfold (<em>P</em> &lt; 0.001), whereas the effect on the AUC(0–∞) and <em>C</em><sub><em>max</em></sub> of pravastatin was not statistically significant [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1884432/#b16" rid="b16" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_137260705">16</a>]. Furthermore, a 14-day pretreatment with St John's wort, an inducer of CYP3A4 and P-glycoprotein, decreased the mean AUC(0–24) of simvastatin acid by 52%, but had no effect on that of pravastatin [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1884432/#b27" rid="b27" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_137260702">27</a>]. These results are in agreement with the present findings and indicate that pravastatin is less susceptible to pharmacokinetic interactions than simvastatin.</p><p id="__p26">Rifampicin decreases the total AUC of fluvastatin, a CYP2C9 substrate [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1884432/#b28" rid="b28" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_137260718">28</a>], by about 50% [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1884432/#b23" rid="b23" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_137260724">23</a>]. Preliminary data also indicate that rifampicin decreases the AUC of atorvastatin by a mean of 78% compared to placebo [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1884432/#b30" rid="b30" class=" bibr popnode">30</a>]. Because the pharmacokinetic properties of the CYP3A4 substrate lovastatin closely resemble those of simvastatin [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1884432/#b31" rid="b31" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_137260727">31</a>, <a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1884432/#b32" rid="b32" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_137260719">32</a>], it is likely that rifampicin will induce the metabolism of lovastatin and lovastatin acid as well. Of the statins studied so far, pravastatin appears to be least susceptible to the potent inducing effects of rifampicin, and therefore seems most suited for use in combination with inducers of CYP enzymes or P-glycoprotein. However, the decrease in pravastatin exposure by rifampicin might be clinically significant in some individuals, and the dose of pravastatin might need adjustment.</p><p id="__p27" class="p p-last">In conclusion, rifampicin had a relatively small but highly variable effect on the pharmacokinetics of pravastatin. The dose of pravastatin might need adjustment in some individuals if long-term treatment with rifampicin is needed.</p></div><div id="__ackid637487" class="tsec sec"><div class="goto jig-ncbiinpagenav-goto-container" id="ui-jig-17"><a class="tgt_dark page-toc-label jig-ncbiinpagenav-goto-heading" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1884432/#" title="Go to other sections in this page" role="button" aria-expanded="false" aria-haspopup="true" id="ui-jig-18">Go to:</a></div><h2 class="head no_bottom_margin ui-helper-clearfix" id="__ackid637487title">Acknowledgments</h2><div class="sec"><p id="__p28">We thank Mr Jouko Laitila, Mrs Kerttu Mårtensson, Mrs Eija Mäkinen-Pulli, and Mrs Lisbet Partanen for technical assistance.</p></div></div><div id="__ref-listid607280" class="tsec sec"><div class="goto jig-ncbiinpagenav-goto-container" id="ui-jig-19"><a class="tgt_dark page-toc-label jig-ncbiinpagenav-goto-heading" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1884432/#" title="Go to other sections in this page" role="button" aria-expanded="false" aria-haspopup="true" id="ui-jig-20">Go to:</a></div><h2 class="head no_bottom_margin ui-helper-clearfix" id="__ref-listid607280title">References</h2><div class="ref-list-sec sec" id="reference-list"><div class="ref-cit-blk half_rhythm" id="b1">1. <span class="citation">Niemi M, Backman JT, Fromm MF, Neuvonen PJ, Kivistö KT. Pharmacokinetic interactions with rifampicin: clinical relevance. <span><span class="ref-journal">Clin Pharmacokinet. </span>2003;<span class="ref-vol">42</span>:819–50.</span>  <span class="nowrap ref pubmed">[<a href="http://www.ncbi.nlm.nih.gov/pubmed/12882588" target="pmc_ext" ref="reftype=pubmed&amp;article-id=1884432&amp;issue-id=144672&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="b2">2. <span class="citation">Kolars JC, Schmiedlin-Ren P, Schuetz JD, Fang C, Watkins PB. Identification of rifampin-inducible P450IIIA4 (CYP3A4) in human small bowel enterocytes. <span><span class="ref-journal">J Clin Invest. </span>1992;<span class="ref-vol">90</span>:1871–8.</span> <span class="nowrap ref pmc">[<a class="int-reflink" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC443248/">PMC free article</a>]</span>  <span class="nowrap ref pubmed">[<a href="http://www.ncbi.nlm.nih.gov/pubmed/1430211" target="pmc_ext" ref="reftype=pubmed&amp;article-id=1884432&amp;issue-id=144672&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="b3">3. <span class="citation">Combalbert J, Fabre I, Fabre G, et al.  Metabolism of cyclosporin A. IV. Purification and identification of the rifampicin-inducible human liver cytochrome P-450 (cyclosporin A oxidase) as a product of P450IIIA gene subfamily. <span><span class="ref-journal">Drug Metab Dispos. </span>1989;<span class="ref-vol">17</span>:197–207.</span>  <span class="nowrap ref pubmed">[<a href="http://www.ncbi.nlm.nih.gov/pubmed/2565211" target="pmc_ext" ref="reftype=pubmed&amp;article-id=1884432&amp;issue-id=144672&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="b4">4. <span class="citation">Greiner B, Eichelbaum M, Fritz P, et al.  The role of intestinal P–glycoprotein in the interaction of digoxin and rifampin. <span><span class="ref-journal">J Clin Invest. </span>1999;<span class="ref-vol">104</span>:147–53.</span> <span class="nowrap ref pmc">[<a class="int-reflink" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC408477/">PMC free article</a>]</span>  <span class="nowrap ref pubmed">[<a href="http://www.ncbi.nlm.nih.gov/pubmed/10411543" target="pmc_ext" ref="reftype=pubmed&amp;article-id=1884432&amp;issue-id=144672&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="b5">5. <span class="citation">Fromm MF, Kauffmann HM, Fritz P, et al.  The effect of rifampin treatment on intestinal expression of human MRP transporters. <span><span class="ref-journal">Am J Pathol. </span>2000;<span class="ref-vol">157</span>:1575–80.</span> <span class="nowrap ref pmc">[<a class="int-reflink" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1885746/">PMC free article</a>]</span>  <span class="nowrap ref pubmed">[<a href="http://www.ncbi.nlm.nih.gov/pubmed/11073816" target="pmc_ext" ref="reftype=pubmed&amp;article-id=1884432&amp;issue-id=144672&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="b6">6. <span class="citation">Kliewer SA, Moore JT, Wade L, et al.  An orphan nuclear receptor activated by pregnanes defines a novel steroid signaling pathway. <span><span class="ref-journal">Cell. </span>1998;<span class="ref-vol">92</span>:73–82.</span>  <span class="nowrap ref pubmed">[<a href="http://www.ncbi.nlm.nih.gov/pubmed/9489701" target="pmc_ext" ref="reftype=pubmed&amp;article-id=1884432&amp;issue-id=144672&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="b7">7. <span class="citation">Lehmann JM, McKee DD, Watson MA, Willson TM, Moore JT, Kliewer SA. The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions. <span><span class="ref-journal">J Clin Invest. </span>1998;<span class="ref-vol">102</span>:1016–23.</span> <span class="nowrap ref pmc">[<a class="int-reflink" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC508967/">PMC free article</a>]</span>  <span class="nowrap ref pubmed">[<a href="http://www.ncbi.nlm.nih.gov/pubmed/9727070" target="pmc_ext" ref="reftype=pubmed&amp;article-id=1884432&amp;issue-id=144672&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="b8">8. <span class="citation">Tirona RG, Leake BF, Wolkoff AW, Kim RB. Human organic anion transporting polypeptide-C (SLC21A6) is a major determinant of rifampin-mediated pregnane X receptor activation. <span><span class="ref-journal">J Pharmacol Exp Ther. </span>2003;<span class="ref-vol">304</span>:223–8.</span>  <span class="nowrap ref pubmed">[<a href="http://www.ncbi.nlm.nih.gov/pubmed/12490595" target="pmc_ext" ref="reftype=pubmed&amp;article-id=1884432&amp;issue-id=144672&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="b9">9. <span class="citation">Kyrklund C, Backman JT, Kivistö KT, Neuvonen M, Laitila J, Neuvonen PJ. Rifampin greatly reduces plasma simvastatin and simvastatin acid concentrations. <span><span class="ref-journal">Clin Pharmacol Ther. </span>2000;<span class="ref-vol">68</span>:592–7.</span>  <span class="nowrap ref pubmed">[<a href="http://www.ncbi.nlm.nih.gov/pubmed/11180018" target="pmc_ext" ref="reftype=pubmed&amp;article-id=1884432&amp;issue-id=144672&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="b10">10. <span class="citation">Jacobsen W, Kirchner G, Hallensleben K, et al.  Small intestinal metabolism of the 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor lovastatin and comparison with pravastatin. <span><span class="ref-journal">J Pharmacol Exp Ther. </span>1999;<span class="ref-vol">291</span>:131–9.</span>  <span class="nowrap ref pubmed">[<a href="http://www.ncbi.nlm.nih.gov/pubmed/10490896" target="pmc_ext" ref="reftype=pubmed&amp;article-id=1884432&amp;issue-id=144672&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="b11">11. <span class="citation">Jacobsen W, Kirchner G, Hallensleben K, et al.  Comparison of cytochrome P-450-dependent metabolism and drug interactions of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors lovastatin and pravastatin in the liver. <span><span class="ref-journal">Drug Metab Dispos. </span>1999;<span class="ref-vol">27</span>:173–9.</span>  <span class="nowrap ref pubmed">[<a href="http://www.ncbi.nlm.nih.gov/pubmed/9929499" target="pmc_ext" ref="reftype=pubmed&amp;article-id=1884432&amp;issue-id=144672&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="b12">12. <span class="citation">Everett DW, Chando TJ, Didonato GC, Singhvi SM, Pan HY, Weinstein SH. Biotransformation of pravastatin sodium in humans. <span><span class="ref-journal">Drug Metab Dispos. </span>1991;<span class="ref-vol">19</span>:740–8.</span>  <span class="nowrap ref pubmed">[<a href="http://www.ncbi.nlm.nih.gov/pubmed/1680649" target="pmc_ext" ref="reftype=pubmed&amp;article-id=1884432&amp;issue-id=144672&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="b13">13. <span class="citation">Yamazaki M, Akiyama S. Ni'inuma K, Nishigaki R, Sugiyama Y. Biliary excretion of pravastatin in rats: contribution of the excretion pathway mediated by canalicular multispecific organic anion transporter. <span><span class="ref-journal">Drug Metab Dispos. </span>1997;<span class="ref-vol">25</span>:1123–9.</span>  <span class="nowrap ref pubmed">[<a href="http://www.ncbi.nlm.nih.gov/pubmed/9321514" target="pmc_ext" ref="reftype=pubmed&amp;article-id=1884432&amp;issue-id=144672&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="b14">14. <span class="citation">Hsiang B, Zhu Y, Wang Z, et al.  A novel human hepatic organic anion transporting polypeptide (OATP2). Identification of a liver-specific human organic anion transporting polypeptide and identification of rat and human hydroxymethylglutaryl-CoA reductase inhibitor transporters. <span><span class="ref-journal">J Biol Chem. </span>1999;<span class="ref-vol">274</span>:37161–8.</span>  <span class="nowrap ref pubmed">[<a href="http://www.ncbi.nlm.nih.gov/pubmed/10601278" target="pmc_ext" ref="reftype=pubmed&amp;article-id=1884432&amp;issue-id=144672&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="b15">15. <span class="citation">Tirona RG, Kim RB. Pharmacogenomics of organic anion-transporting polypeptides (OATP) <span><span class="ref-journal">Adv Drug Deliv Rev. </span>2002;<span class="ref-vol">54</span>:1343–52.</span>  <span class="nowrap ref pubmed">[<a href="http://www.ncbi.nlm.nih.gov/pubmed/12406649" target="pmc_ext" ref="reftype=pubmed&amp;article-id=1884432&amp;issue-id=144672&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="b16">16. <span class="citation">Neuvonen PJ, Kantola T, Kivistö KT. Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole. <span><span class="ref-journal">Clin Pharmacol Ther. </span>1998;<span class="ref-vol">63</span>:332–41.</span>  <span class="nowrap ref pubmed">[<a href="http://www.ncbi.nlm.nih.gov/pubmed/9542477" target="pmc_ext" ref="reftype=pubmed&amp;article-id=1884432&amp;issue-id=144672&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="b17">17. <span class="citation">Fichtenbaum CJ, Gerber JG, Rosenkranz SL, et al.  Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers. <span><span class="ref-journal">ACTG Study A5047 AIDS. </span>2002;<span class="ref-vol">16</span>:569–77.</span>  <span class="nowrap ref pubmed">[<a href="http://www.ncbi.nlm.nih.gov/pubmed/11873000" target="pmc_ext" ref="reftype=pubmed&amp;article-id=1884432&amp;issue-id=144672&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="b18">18. <span class="citation">Mulvana D, Jemal M, Pulver SC. Quantitative determination of pravastatin and its biotransformation products in human serum by turbo ion spray LC/MS/MS. <span><span class="ref-journal">J Pharm Biomed Anal. </span>2000;<span class="ref-vol">23</span>:851–66.</span>  <span class="nowrap ref pubmed">[<a href="http://www.ncbi.nlm.nih.gov/pubmed/11022911" target="pmc_ext" ref="reftype=pubmed&amp;article-id=1884432&amp;issue-id=144672&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="b19">19. <span class="citation">Bogman K, Peyer AK, Torok M, Kusters E, Drewe J. HMG-CoA reductase inhibitors and P-glycoprotein modulation. <span><span class="ref-journal">Br J Pharmacol. </span>2001;<span class="ref-vol">132</span>:1183–92.</span> <span class="nowrap ref pmc">[<a class="int-reflink" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1572659/">PMC free article</a>]</span>  <span class="nowrap ref pubmed">[<a href="http://www.ncbi.nlm.nih.gov/pubmed/11250868" target="pmc_ext" ref="reftype=pubmed&amp;article-id=1884432&amp;issue-id=144672&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="b20">20. <span class="citation">Zamora JM, Pearce HL, Beck WT. Physical-chemical properties shared by compounds that modulate multidrug resistance in human leukemic cells. <span><span class="ref-journal">Mol Pharmacol. </span>1988;<span class="ref-vol">33</span>:454–62.</span>  <span class="nowrap ref pubmed">[<a href="http://www.ncbi.nlm.nih.gov/pubmed/3162758" target="pmc_ext" ref="reftype=pubmed&amp;article-id=1884432&amp;issue-id=144672&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="b21">21. <span class="citation">Ecker G, Chiba P. Structure-activity-relationship studies on modulators of the multidrug transporter P-glycoprotein – an overview. <span><span class="ref-journal">Wien Klin Wochenschr. </span>1995;<span class="ref-vol">107</span>:681–6.</span>  <span class="nowrap ref pubmed">[<a href="http://www.ncbi.nlm.nih.gov/pubmed/8533428" target="pmc_ext" ref="reftype=pubmed&amp;article-id=1884432&amp;issue-id=144672&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="b22">22. <span class="citation">Sandusky GE, Mintze KS, Pratt SE, Dantzig AH. Expression of multidrug resistance-associated protein 2 (MRP2) in normal human tissues and carcinomas using tissue microarrays. <span><span class="ref-journal">Histopathology. </span>2002;<span class="ref-vol">41</span>:65–74.</span>  <span class="nowrap ref pubmed">[<a href="http://www.ncbi.nlm.nih.gov/pubmed/12121239" target="pmc_ext" ref="reftype=pubmed&amp;article-id=1884432&amp;issue-id=144672&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="b23">23. <span class="citation">Vavricka SR, Van Montfoort J, Ha HR, Meier PJ, Fattinger K. Interactions of rifamycin SV and rifampicin with organic anion uptake systems of human liver. <span><span class="ref-journal">Hepatology. </span>2002;<span class="ref-vol">36</span>:164–72.</span>  <span class="nowrap ref pubmed">[<a href="http://www.ncbi.nlm.nih.gov/pubmed/12085361" target="pmc_ext" ref="reftype=pubmed&amp;article-id=1884432&amp;issue-id=144672&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="b24">24. <span class="citation">Doostdar H, Grant MH, Melvin WT, Wolf CR, Burke MD. The effects of inducing agents on cytochrome P450 and UDP-glucuronyltransferase activities in human HEPG2 hepatoma cells. <span><span class="ref-journal">Biochem Pharmacol. </span>1993;<span class="ref-vol">46</span>:629–35.</span>  <span class="nowrap ref pubmed">[<a href="http://www.ncbi.nlm.nih.gov/pubmed/8395842" target="pmc_ext" ref="reftype=pubmed&amp;article-id=1884432&amp;issue-id=144672&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="b25">25. <span class="citation">Prescott LF, Critchley JA, Balali-Mood M, Pentland B. Effects of microsomal enzyme induction on paracetamol metabolism in man. <span><span class="ref-journal">Br J Clin Pharmacol. </span>1981;<span class="ref-vol">12</span>:149–53.</span> <span class="nowrap ref pmc">[<a class="int-reflink" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1401868/">PMC free article</a>]</span>  <span class="nowrap ref pubmed">[<a href="http://www.ncbi.nlm.nih.gov/pubmed/7306429" target="pmc_ext" ref="reftype=pubmed&amp;article-id=1884432&amp;issue-id=144672&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="b26">26. <span class="citation">Dilger K, Hofmann U, Klotz U. Enzyme induction in the elderly. effect of rifampin on the pharmacokinetics and pharmacodynamics of propafenone. <span><span class="ref-journal">Clin Pharmacol Ther. </span>2000;<span class="ref-vol">67</span>:512–20.</span>  <span class="nowrap ref pubmed">[<a href="http://www.ncbi.nlm.nih.gov/pubmed/10824630" target="pmc_ext" ref="reftype=pubmed&amp;article-id=1884432&amp;issue-id=144672&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="b27">27. <span class="citation">Sugimoto K, Ohmori M, Tsuruoka S, et al.  Different effects of St John's wort on the pharmacokinetics of simvastatin and pravastatin. <span><span class="ref-journal">Clin Pharmacol Ther. </span>2001;<span class="ref-vol">70</span>:518–24.</span>  <span class="nowrap ref pubmed">[<a href="http://www.ncbi.nlm.nih.gov/pubmed/11753267" target="pmc_ext" ref="reftype=pubmed&amp;article-id=1884432&amp;issue-id=144672&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="b28">28. <span class="citation">Fischer V, Johanson L, Heitz F, et al.  The 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor fluvastatin: effect on human cytochrome P-450 and implications for metabolic drug interactions. <span><span class="ref-journal">Drug Metab Dispos. </span>1999;<span class="ref-vol">27</span>:410–16.</span>  <span class="nowrap ref pubmed">[<a href="http://www.ncbi.nlm.nih.gov/pubmed/10064574" target="pmc_ext" ref="reftype=pubmed&amp;article-id=1884432&amp;issue-id=144672&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="b29">29. <span class="citation">Jokubaitis LA. Updated clinical safety experience with fluvastatin. <span><span class="ref-journal">Am J Cardiol. </span>1994;<span class="ref-vol">73</span>:18D–24D.</span>  <span class="nowrap ref pubmed">[<a href="http://www.ncbi.nlm.nih.gov/pubmed/8198019" target="pmc_ext" ref="reftype=pubmed&amp;article-id=1884432&amp;issue-id=144672&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="b30">30. <span class="citation">Backman JT, Luurila H, Neuvonen M, Neuvonen PJ. Rifampicin markedly decreases the concentrations of atorvastatin and its metabolites [abstract] <span class="ref-journal">18th European workshop on drug metabolism Abstract book.</span> 2002. p. 83.</span></div><div class="ref-cit-blk half_rhythm" id="b31">31. <span class="citation">Neuvonen PJ, Jalava KM. Itraconazole drastically increases plasma concentrations of lovastatin and lovastatin acid. <span><span class="ref-journal">Clin Pharmacol Ther. </span>1996;<span class="ref-vol">60</span>:54–61.</span>  <span class="nowrap ref pubmed">[<a href="http://www.ncbi.nlm.nih.gov/pubmed/8689812" target="pmc_ext" ref="reftype=pubmed&amp;article-id=1884432&amp;issue-id=144672&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="b32">32. <span class="citation">Vickers S, Duncan CA, Vyas KP, et al.  In vitro and in vivo biotransformation of simvastatin, an inhibitor of HMG CoA reductase. <span><span class="ref-journal">Drug Metab Dispos. </span>1990;<span class="ref-vol">18</span>:476–83.</span>  <span class="nowrap ref pubmed">[<a href="http://www.ncbi.nlm.nih.gov/pubmed/1976071" target="pmc_ext" ref="reftype=pubmed&amp;article-id=1884432&amp;issue-id=144672&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div></div></div><div style="display: none; width: 200px; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true" class="ui-helper-reset ui-ncbipopper-wrapper ui-ncbilinksmenu"><ul id="ui-ncbiinpagenav-2"><li><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1884432/#__abstractid623016title">Abstract</a></li><li><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1884432/#__sec5title">Introduction</a></li><li><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1884432/#__sec6title">Methods</a></li><li><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1884432/#__sec13title">Results</a></li><li><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1884432/#__sec14title">Discussion</a></li><li><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1884432/#__ackid637487title">Acknowledgments</a></li><li><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1884432/#__ref-listid607280title">References</a></li></ul></div></div><!--post-content--><hr class="whole_rhythm no_bottom_margin"><div class="courtesy-note no_margin small">Articles from <span class="acknowledgment-journal-title">British Journal of Clinical Pharmacology</span> are provided here courtesy of <strong>British Pharmacological Society</strong></div></div>
            
            
        
            
        </div>
        <!-- Book content -->
    </div>
    
    <div id="rightcolumn" class="four_col col last">
        <!-- Custom content above discovery portlets -->
        <div class="col6">
            
        </div>
        
        <div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><div class="try-button"><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1884432/?report=reader"><img src="./PMC1884432_files/3838809" alt="PubReader format: click here to try"></a></div><div class="format-menu"><h2>Formats:</h2><ul><li class="selected">Article</li> | <li><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1884432/?report=reader">PubReader</a></li> | <li class="epub-link"><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1884432/epub/">ePub (beta)</a></li> | <li><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1884432/pdf/bcp0057-0181.pdf">PDF (126K)</a></li> | <li><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1884432/#" data-citationid="PMC1884432" class="citationexporter ctxp" role="button" aria-expanded="false" aria-haspopup="true">Citation</a></li></ul></div></div><div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="share-buttons"><h2>Share</h2><ul><li class="facebook"><a href="https://www.facebook.com/sharer/sharer.php?u=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC1884432%2F" role="button" aria-expanded="false" aria-haspopup="true" target="_blank"><img src="./PMC1884432_files/4047626" alt="Share on Facebook">
                             Facebook
                        </a></li><li class="twitter"><a href="https://twitter.com/intent/tweet?url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC1884432%2F&amp;text=Effect%20of%20rifampicin%20on%20pravastatin%20pharmacokinetics%20in%20healthy%20subjects" role="button" aria-expanded="false" aria-haspopup="true" target="_blank"><img src="./PMC1884432_files/4047627" alt="Share on Twitter">
                             Twitter
                        </a></li><li class="gplus"><a href="https://plus.google.com/share?url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC1884432%2F" role="button" aria-expanded="false" aria-haspopup="true" target="_blank"><img src="./PMC1884432_files/4047628" alt="Share on Google Plus">
                             Google+
                        </a></li></ul></div>
        
        <div id="ajax-portlets" data-pmid="14748817" data-aiid="1884432" data-aid="1884432" data-iid="144672" data-domainid="279" data-domain="brjclinpharm" data-accid="PMC1884432" data-md5="be03b577038d95a3c00b863a6f1bdc12"><img src="./PMC1884432_files/3631476" align="absmiddle" alt="Loading..."> Loading portlets...</div>
                
        <!-- Custom content below discovery portlets -->
        <div class="col7">
            
        </div>
    </div>
</div>

<!-- Custom content after all -->
<div class="col8">
    
</div>
<div class="col9">
    
</div>

<script src="./PMC1884432_files/jquery.scrollTo-1.4.2.js"></script>
<script>
    (function($){
        $('.skiplink').each(function(i, item){
            var href = $($(item).attr('href'));
            href.attr('tabindex', '-1').addClass('skiptarget'); // ensure the target can receive focus
            $(item).on('click', function(event){
                event.preventDefault();
                $.scrollTo(href, 0, {
                    onAfter: function(){
                        href.focus();
                    }
                });
            });
        });
    })(jQuery);
</script>



<div id="body-link-poppers"></div>
                        </div>
                        <div class="bottom">
                            
                            <div id="NCBIFooter_dynamic">
    <div class="breadcrumbs">You are here: 
            <span id="breadcrumb_text"><a href="http://www.ncbi.nlm.nih.gov/guide/">NCBI</a> &gt; <a href="http://www.ncbi.nlm.nih.gov/guide/literature/">Literature</a> &gt; <a href="http://www.ncbi.nlm.nih.gov/pmc/">PubMed Central (PMC)</a></span></div>
    <a id="help-desk-link" class="help_desk jig-ncbihelpwindow" target="_blank" href="http://www.ncbi.nlm.nih.gov/sites/ehelp?&amp;Ncbi_App=pmc&amp;Db=pmc&amp;Page=literature&amp;Snapshot=/projects/PMC/PMCViewer@4.35&amp;Time=2016-06-23T14:15:44-04:00&amp;Host=ptpmc201">Write to the Help Desk</a>
    
</div>

                            <div class="footer" id="footer">
    
    <div class="subfooter"> </div><script type="text/javascript" src="./PMC1884432_files/preloaderWidget.js"> </script>
    <div id="external-disclaimer" class="offscreen_noflow">
        External link. Please review our <a href="http://www.nlm.nih.gov/privacy.html">privacy policy</a>.
    </div>    
    <div id="ncbifooter" class="contact_info">      
        <div id="footer-contents-right">
            <div id="nlm_thumb_logo">
                <a href="http://www.nlm.nih.gov/" title="NLM">NLM</a>
            </div>
            <div id="nih_thumb_logo">
                <a href="http://www.nih.gov/" title="NIH">NIH</a>
            </div>
            <div id="hhs_thumb_logo">
                <a href="http://www.dhhs.gov/" title="DHHS">DHHS</a>
            </div>
            <div id="usagov_thumb_logo">
                <a href="http://www.usa.gov/" title="USA.gov">USA.gov</a>
            </div>         
        </div>
        
        <div id="footer-contents-left">
            
            <a href="http://www.ncbi.nlm.nih.gov/About/disclaimer.html">Copyright</a> | <a href="http://www.ncbi.nlm.nih.gov/About/disclaimer.html#disclaimer">Disclaimer</a> |
            <a href="http://www.nlm.nih.gov/privacy.html" class="newdomain">Privacy</a> | 
            <a href="http://www.ncbi.nlm.nih.gov/guide/browsers/">Browsers</a> | <a href="http://www.nlm.nih.gov/accessibility.html">Accessibility</a> | <a href="http://www.ncbi.nlm.nih.gov/About/glance/contact_info.html">Contact</a>
            <p class="address vcard">
                <span class="url">
                    <a class="fn url newdomain" href="http://www.ncbi.nlm.nih.gov/">National Center for
                        Biotechnology Information</a>,
                </span> <span class="org url"><a href="http://www.nlm.nih.gov/">U.S. National Library of Medicine</a></span>
                <span class="adr">
                    <span class="street-address">8600 Rockville Pike</span>, <span class="locality">Bethesda</span>
                    <span class="region">MD</span>, <span class="postal-code">20894</span>
                    <span class="country-name">USA</span>
                </span>
            </p>
        </div>
    </div>
    <script type="text/javascript" src="./PMC1884432_files/InstrumentPageStarterJS.js"> </script>    
    <script type="text/javascript" src="./PMC1884432_files/hfjs2.js"> </script>
</div>
                        </div>
                    </div>
                    <!--/.page-->
                </div>
                <!--/.wrap-->
            </div><!-- /.twelve_col -->
        <div style="display: none; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true" class="ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic">External link. Please review our <a href="http://www.nlm.nih.gov/privacy.html">privacy policy</a>.</div><div class="ui-ncbiautocomplete-holder shadow ui-ncbiautocomplete-holder-clearfix" aria-live="assertive" style="display: none; top: 63.5938px; left: 408.188px; width: 670px; z-index: 1001;"><ul class="ui-ncbiautocomplete-options" role="listbox" aria-activedescendant="term"></ul><div class="ui-ncbiautocomplete-actions shadow" style="display: none;"><a class="ui-ncbiautocomplete-link-pref" style="display: none;">Preferences</a><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1884432/#" class="ui-ncbiautocomplete-link-off ui-ncbiautocomplete-link-pref-right" style="display: none;">Turn off</a></div></div></div>
        <!-- /.grid -->

        <span class="PAFAppResources"></span>
        
        <!-- BESelector tab -->
        
        
        
        <noscript>&lt;img alt="statistics" src="/stat?jsdisabled=true&amp;amp;ncbi_db=pmc&amp;amp;ncbi_pdid=article&amp;amp;ncbi_acc=&amp;amp;ncbi_domain=brjclinpharm&amp;amp;ncbi_report=record&amp;amp;ncbi_type=fulltext&amp;amp;ncbi_objectid=&amp;amp;ncbi_pcid=/articles/PMC1884432/&amp;amp;ncbi_app=pmc" /&gt;</noscript>
        
        
        <!-- usually for JS scripts at page bottom -->
        <!--<component id="PageFixtures" label="styles"></component>-->
    

<!-- F4FC7E8376854741_0014SID /projects/PMC/PMCViewer@4.35 ptpmc201 v4.1.r480124 Mon, Sep 28 2015 02:46:19 -->

<script type="text/javascript" src="./PMC1884432_files/4065628.js" snapshot="pmc"></script>
<div class="ui-dialog ui-widget ui-widget-content ui-corner-all ui-front" tabindex="-1" role="dialog" aria-describedby="epubDialog" aria-labelledby="ui-id-1" style="display: none;"><div class="ui-dialog-titlebar ui-widget-header ui-corner-all ui-helper-clearfix"><span id="ui-id-1" class="ui-dialog-title">Making articles easier to read in PMC</span><button type="button" class="ui-button ui-widget ui-state-default ui-corner-all ui-button-icon-only ui-dialog-titlebar-close" role="button" title="Close"><span class="ui-button-icon-primary ui-icon ui-icon-closethick"></span><span class="ui-button-text">Close</span></button></div><div id="epubDialog" style="display: block;" class="ui-dialog-content ui-widget-content">  <p>We are experimenting with display styles that make it easier to read articles     in PMC.     Our first effort uses eBook readers, which have several "ease of reading"     features already built in.</p>  <p>These PMC articles are best viewed in the <em>iBooks     reader</em>. You may notice problems with the display of certain parts of an article     in other eReaders.</p>  <div class="ui-dialog-buttonpane ui-widget-content ui-helper-clearfix"><button id="cancelEpub" class="ui-state-default ui-corner-all">Cancel</button><button id="downloadEpub" style="float: left" class="ui-state-default ui-corner-all">Download article</button></div>          </div></div><ul class="print-log"><li></li></ul></body></html>